Perspective Therapeutics (FRA:AAJ) EV-to-EBIT : -18.50 (As of May. 24, 2024)

Perspective Therapeutics EV-to-EBIT Chart

Perspective Therapeutics Annual Data
	Trend	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					-4.23	-10.61	-14.60	1.55	-2.66

Perspective Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-7.52	-5.88	-1.86	-2.66	-12.64

Competitive Comparison of Perspective Therapeutics's EV-to-EBIT

For the Medical Devices subindustry, Perspective Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perspective Therapeutics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's EV-to-EBIT falls into.

Perspective Therapeutics EV-to-EBIT Calculation

Perspective Therapeutics's EV-to-EBIT for today is calculated as:

Perspective Therapeutics's current Enterprise Value is €704.32 Mil.
Perspective Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-38.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics  (FRA:AAJ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Perspective Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Perspective Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €482.06 Mil.
Perspective Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-38.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Perspective Therapeutics (FRA:AAJ) Business Description